Table 3.
AE, n (%) | Avelumab + Lorlatinib (n = 31) | Avelumab + Crizotinib (n = 12) |
---|---|---|
TEAE, any grade | 30 (97) | 12 (100) |
Grade ≥3 | 23 (74) | 7 (58) |
TRAE, any grade | 28 (90) | 12 (100) |
Grade ≥3 | 16 (52) | 6 (50) |
TEAE leading to permanent discontinuation of any study drug | 10 (32) | 6 (50) |
TEAE leading to permanent discontinuation of all study drugs | 1 (3) | 3 (25) |
TRAE leading to permanent discontinuation of avelumab | 9 (29) | 2 (17) |
TRAE leading to permanent discontinuation of crizotinib | 0 | 5 (42) |
TRAE leading to permanent discontinuation of lorlatinib | 2 (7) | 0 |
TEAE leading to death | 4 (13) | 1 (8) |
TRAE leading to death | 1 (3) | 0 |
IRR (AE of special interest) | 9 (29) | 5 (42) |
AE, adverse event; IRR, infusion-related reaction; TEAE, treatment-emergent AE; TRAE, treatment-related AE.